Evommune | Chronic Inflammatory Disease Therapies | Pipeline
Advancing a broad pipeline of differentiated product candidates for chronic inflammatory diseases.
Development Pipeline
Driving meaningful advances to address chronic inflammation.
We’re committed to evolving immunology, with a pipeline of programs specifically designed to address inflammatory diseases with clear, unmet needs. The disease pathways under investigation by Evommune exert influence on a multitude of disease areas, and the modulation of mast cell, sensory neuron and T-cell activity shows promise in multiple established patient populations.
| Program |
Target |
Indication |
| EVO756 |
MRGPRX2 |
Atopic Dermatitis, Migraine, Other Indications |
| EVO301 |
IL-18 |
Atopic Dermatitis, Ulcerative Colitis, Other Indications |
| Program |
Target |
Indication |
Stage |
| EVO756 |
MRGPRX2 |
Atopic Dermatitis, Migraine, Other Indications |
Phase 2 |
| EVO301 |
IL-18 |
Atopic Dermatitis, Ulcerative Colitis, Other Indications |
Phase 2 |
Learn about our ongoing clinical trials for our investigational therapies.
View Clinical Trials